Company profile: Poolbeg Pharma
1.1 - Company Overview
Company description
- Provider of clinical-stage research and development of novel treatments for infectious diseases, including POLB 001, an oral small molecule for cancer immunotherapy-induced cytokine release syndrome and severe influenza; AI-powered drug discovery leveraging human challenge trial data; and an oral GLP-1 agonist delivery system targeting obesity and other metabolic diseases.
Products and services
- AI Powered Drug Discovery: AI-driven platform analyzes data from human challenge trials to identify drug targets and treatments for infectious diseases
- Oral GLP-1 Agonist: Custom-engineered delivery system carries metabolic peptide cargo targeting obesity and other metabolic diseases, aiming to deliver an oral alternative to injectable GLP-1 treatments
- POLB 001: Clinical-stage oral small molecule engineered to counter cancer immunotherapy-induced Cytokine Release Syndrome and severe influenza, demonstrating efficacy in reducing inflammation and cytokine levels
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Poolbeg Pharma
OM Pharma
HQ: Switzerland
Website
- Description: Provider of microbial-derived immunotherapeutic products addressing acute and chronic immunological disorders from infections and inflammation, operating worldwide through partners and investing in R&D. Products include Broncho-Vaxom to regulate the immune system and prevent recurrent respiratory infections, Uro-Vaxom to treat and prevent recurrent lower urinary tract infections, and Dicynone for capillary hemorrhage prevention and treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OM Pharma company profile →
Coris BioConcept
HQ: Belgium
Website
- Description: Provider of rapid diagnostic kits, developing, marketing and selling assays including RESIST Range for antibiotic resistance (carbapenemase-producing organisms), Legionella K-SeT lateral flow test for Legionella pneumophila, HAT Sero K-SeT for Trypanosoma brucei gambiense, BL-RED electrochemical test for bacterial hydrolysis related to 3GC antibiotics, Giardia-Strip dipstick test, and RT-LAMP fluorescence assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coris BioConcept company profile →
Anacor Pharmaceuticals
HQ: United States
Website
- Description: Provider of small-molecule therapeutics based on a boron chemistry platform, focused on developing topical treatments for fungal, bacterial, and inflammatory diseases, including its primary product candidate AN2690, a novel topical antifungal.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anacor Pharmaceuticals company profile →
Q-linea
HQ: Sweden
Website
- Description: Provider of applications and systems for detecting, for example, biological warfare agents; a privately held company that develops and sells these detection applications and systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Q-linea company profile →
Prodesse
HQ: United States
Website
- Description: Provider of molecular diagnostic reagents for infectious disease applications, with three FDA 510(k) cleared products in the United States and two CE-marked products in Europe; products can be used with various nucleic acid extraction and real-time PCR.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prodesse company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Poolbeg Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Poolbeg Pharma
2.2 - Growth funds investing in similar companies to Poolbeg Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Poolbeg Pharma
4.2 - Public trading comparable groups for Poolbeg Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →